Quarterly report pursuant to Section 13 or 15(d)

Collaboration and License Agreements and Supply Agreements - Summary of Recognized Revenue (Details)

v3.21.2
Collaboration and License Agreements and Supply Agreements - Summary of Recognized Revenue (Details) - USD ($)
$ in Thousands
 3 Months Ended 6 Months Ended
Jun. 30, 2021
Jun. 30, 2020
Jun. 30, 2021
Jun. 30, 2020
Revenue Recognition Multiple Deliverable Arrangements [Line Items]        
Total revenue $ 28,049 $ 9,469 $ 42,709 $ 16,621
Collaboration and License Agreements and Supply Agreements        
Revenue Recognition Multiple Deliverable Arrangements [Line Items]        
Total revenue 28,049 9,469 42,709 16,621
Collaboration and License Agreements and Supply Agreements | Bristol-Myers Squibb Company ("BMS")        
Revenue Recognition Multiple Deliverable Arrangements [Line Items]        
Total revenue 5,427 1,509 6,666 3,554
Collaboration and License Agreements and Supply Agreements | Merck        
Revenue Recognition Multiple Deliverable Arrangements [Line Items]        
Total revenue 19,878 7,005 31,761 9,782
Collaboration and License Agreements and Supply Agreements | Merck KGaA, Darmstadt, Germany "EMD Serono")        
Revenue Recognition Multiple Deliverable Arrangements [Line Items]        
Total revenue 2,375 855 2,595 3,149
Collaboration and License Agreements and Supply Agreements | Vaxcyte, Inc.        
Revenue Recognition Multiple Deliverable Arrangements [Line Items]        
Total revenue 369 100 1,687 136
BMS Agreement and the 2018 BMS Master Services Agreement        
Revenue Recognition Multiple Deliverable Arrangements [Line Items]        
Revenues 5,427 1,509 6,666 3,554
BMS Agreement and the 2018 BMS Master Services Agreement | Ongoing Performance Related to Unsatisfied Performance Obligations        
Revenue Recognition Multiple Deliverable Arrangements [Line Items]        
Revenues   990   1,974
BMS Agreement and the 2018 BMS Master Services Agreement | Research and Development Services        
Revenue Recognition Multiple Deliverable Arrangements [Line Items]        
Revenues 211 253 513 400
BMS Agreement and the 2018 BMS Master Services Agreement | Materials Supply        
Revenue Recognition Multiple Deliverable Arrangements [Line Items]        
Revenues 5,216 266 6,153 1,180
2020 Merck Master Services Agreement        
Revenue Recognition Multiple Deliverable Arrangements [Line Items]        
Total revenue 19,878 7,005 31,761 9,782
2020 Merck Master Services Agreement | Ongoing Performance Related to Unsatisfied Performance Obligations        
Revenue Recognition Multiple Deliverable Arrangements [Line Items]        
Total revenue 18,322 5,202 27,383 6,141
2020 Merck Master Services Agreement | Research and Development Services        
Revenue Recognition Multiple Deliverable Arrangements [Line Items]        
Total revenue 705 1,275 1,909 2,513
2020 Merck Master Services Agreement | Financing Component on Unearned Revenue        
Revenue Recognition Multiple Deliverable Arrangements [Line Items]        
Total revenue 181 528 412 1,128
2020 Merck Master Services Agreement | Materials Supply        
Revenue Recognition Multiple Deliverable Arrangements [Line Items]        
Total revenue 670   2,057  
2019 EMD Serono Supply Agreement        
Revenue Recognition Multiple Deliverable Arrangements [Line Items]        
Total revenue 2,375 855 2,595 3,149
2019 EMD Serono Supply Agreement | Contingent Payment Earned        
Revenue Recognition Multiple Deliverable Arrangements [Line Items]        
Total revenue 2,000   2,000  
2019 EMD Serono Supply Agreement | Research and Development Services        
Revenue Recognition Multiple Deliverable Arrangements [Line Items]        
Total revenue 126 492 289 823
2019 EMD Serono Supply Agreement | Materials Supply        
Revenue Recognition Multiple Deliverable Arrangements [Line Items]        
Total revenue 249 363 306 2,326
Supply Agreement | Vaxcyte, Inc.        
Revenue Recognition Multiple Deliverable Arrangements [Line Items]        
Total revenue 369 100 1,687 136
Supply Agreement | Vaxcyte, Inc. | Research and Development Services        
Revenue Recognition Multiple Deliverable Arrangements [Line Items]        
Total revenue 264   469  
Supply Agreement | Vaxcyte, Inc. | Materials Supply        
Revenue Recognition Multiple Deliverable Arrangements [Line Items]        
Total revenue $ 105 $ 100 $ 1,218 $ 136